Results 11 to 20 of about 69,031,262 (351)

Fluvoxamine for the treatment of COVID-19

The Lancet Global Health, 2022
Fluvoxamine is a selective serotonin reuptake inhibitor (SSRI) that has been approved for the treatment of depression, obsessive-compulsive disorder, and a variety of anxiety disorders; it is available as an oral preparation. Fluvoxamine has not been approved for the treatment of infections, but has been used in the early treatment of people with mild ...
Dodds, Michael G, Doyle, Eileen B, Reiersen, Angela M, Brown, Fran, Rayner, Craig R   +4 more
  +13 more sources

Treatment of COVID-19

Proceedings for Annual Meeting of The Japanese Pharmacological Society, 2021
Coronavirus is a type of single-stranded RNA virus with a lipid bilayer called an envelope on the outside, and it looks like a corona under an electron microscope. It cannot self-regenerate, attaches to and enters human cells via ACE2 receptors, and proliferates within the human cells.
Qu, Jie-Ming, Cao, Bin, Chen, Rong-Chang
openaire   +4 more sources

Tocilizumab for the treatment of COVID-19 [PDF]

Expert Opinion on Biological Therapy, 2021
It has been one year since the first cases of pneumonia caused by the now designated as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were reported from Wuhan.
Fernández-Ruiz, Mario, López-Medrano, Francisco, Aguado, José María   +2 more
openaire   +3 more sources

Expert Report for the UK Covid-19 Public Inquiry: Module 2B: Welsh Government core political and administrative decision-making in relation to the Covid-19 pandemic [PDF]

Expect Report for the UK Covid-19 Public Inquiry: Module 2B: Welsh Government core political and administrative decision-making in relation to the Covid-19 ...
Wincott, Daniel, UK Covid-19 Public Inquiry   +1 more
core   +6 more sources

Pharmacological treatments of COVID-19 [PDF]

Pharmacological Reports, 2020
The viral infection due to the new coronavirus or coronavirus disease 2019 (COVID-19), which was reported for the first time in December 2019, was named by the World Health Organization (WHO) as Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV2), because of the very similar genome and also its related symptoms to SARS-CoV1.
Sahebnasagh, Adeleh, Avan, Razieh, Saghafi, Fatemeh, Mojtahedzadeh, Mojataba, Sadremomtaz, Afsaneh, Arasteh, Omid, Tanzifi, Asal, Faramarzi, Fatemeh, Negarandeh, Reza, Safdari, Mohammadreza, Khataminia, Masoud, Rezai Ghaleno, Hassan, Habtemariam, Solomon, Khoshi, Amirhosein   +13 more
openaire   +3 more sources

COVID-19: Acing the Treatment [PDF]

Medical Principles and Practice, 2021
Angiotensin converting enzyme 2 is the functional receptor that the SARS-Cov-2 virus requires to enter cells and cause dysregulated inflammatory conditions that contribute towards acute lung injuries. The renin-angiotensin-aldosterone system with its physiological surveillance and regulation system can be implicated in both harm and therapeutic benefit.
Jez Hunter, Puskar Bura, Richard King, George Thomson   +3 more
openaire   +1 more source

COVID-19 vaccination for people with disabilities [PDF]

, 2021
Internationally, people with disabilities have been disproportionately impacted by COVID-19, accounting for nearly 60% of COVID-19 deaths in the UK and overall higher mortality rates based on social, clinical, and demographic factors.
Stall, Nathan M, Razak, Fahad, Downer, Matthew B, Brown, Hilary, Campanella, Sabrina, Cooper, Jane, Rotenberg, Sara, Rochon, Paula A, Porch, Wendy, Bell, Sandi, Schull, Michael, Safar, Yousef, Lunsky, Yona, Katz, Gabrielle M, Yona Lunsky, Sabrina Campanella, Fahad Razak, Wendy Porch, Yousef Safar, Michael Schull, Sara Rotenberg, Gabrielle M. Katz, Sandi Bell, Nathan M. Stall, Hilary Brown, Jane Cooper, Paula A. Rochon, Matthew B. Downer   +27 more
core   +1 more source

Lung Fibrosis after COVID-19: Treatment Prospects

Pharmaceuticals, 2021
At the end of 2019, a highly contagious infection began its ominous conquest of the world. It was soon discovered that the disease was caused by a novel coronavirus designated as SARS-CoV-2, and the disease was thus abbreviated to COVID-19 (COVID).
E. Bazdyrev, Polina Rusina, M. Panova, F. Novikov, Ivan Grishagin, V. Nebolsin   +5 more
semanticscholar   +1 more source

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

International Journal of Antimicrobial Agents, 2020
Background Chloroquine and hydroxychloroquine have been found to be efficient on SARS-CoV-2, and reported to be efficient in Chinese COV-19 patients. We evaluate the effect of hydroxychloroquine on respiratory viral loads.
P. Gautret, J. Lagier, P. Parola, V. Hoang, L. Meddeb, M. Mailhe, B. Doudier, J. Courjon, V. Giordanengo, V. E. Vieira, Hervé Tissot Dupont, S. Honoré, P. Colson, E. Chabrière, B. La Scola, J. Rolain, P. Brouqui, D. Raoult   +17 more
semanticscholar   +1 more source

Assessing the effects of exposure to a SARS-CoV-2 re-positive patient in healthcare personnel

BMC Research Notes, 2020
Objective To evaluate whether patients with COVID-19 who have tested re-positive with the PCR test for the SARS-CoV-2 virus are infectious is a challenge in the current circumstances.
Yoshihiko Ogawa, Koji Nishida, Iwao Gohma, Kei Kasahara, Hisakazu Yano   +4 more
doaj   +1 more source